交易中 05-19 09:47:45 美东时间
-0.550
-0.81%
今日重点评级关注:Ascendiant Capital:维持NRX Pharmaceuticals"买入"评级,目标价从48美元升至49美元;Chardan Capital:维持Intellia Therapeutics"买入"评级,目标价从27美元升至30美元
04-28 10:07
今日重点评级关注:瑞银:维持SS&C科技"买入"评级,目标价从112美元升至115美元;Piper Sandler:维持儒博实业"超配"评级,目标价从530美元升至540美元
04-27 14:04
Stephens & Co. analyst Matt Olney maintains Southern Missouri Bancorp (NASDAQ:SMBC) with a Overweight and raises the price target from $72 to $76.
04-24 21:08
今日重点评级关注:Ascendiant Capital:维持RenovoRx"买入"评级,目标价从13美元升至13.5美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从8.25美元升至9美元
04-10 18:27
Keefe, Bruyette & Woods analyst Kelly Motta maintains Southern Missouri Bancorp (NASDAQ:SMBC) with a Market Perform and raises the price target from $64 to $65.
04-10 02:04
今日重点评级关注:Oppenheimer:维持Pelthos Therapeutics"跑赢大市"评级,目标价从57美元升至60美元;Small Cap Consumer Research:维持Lands' End"买入"评级,目标价从20美元升至45美元
01-27 10:02
今日重点评级关注:RBC Capital:维持Compass Pathways"跑赢大市"评级,目标价从16美元升至21美元;RBC Capital:维持GH Research"跑赢大市"评级,目标价从33美元升至40美元
01-26 14:32
Southern Missouri Bancorp, Inc. ("Company") (NASDAQ:SMBC), the parent corporation of Southern Bank ("Bank"), today announced preliminary net income for the second quarter of fiscal 2026 of $18.2 million, an increase of
01-22 06:37
Southern Missouri Bancorp (NASDAQ:SMBC) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.50 by 7.78 percent. This is a 24.62 percent increase over earnings of $1.30 per share
01-22 06:36